Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 16;11(5):990.
doi: 10.3390/vaccines11050990.

Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium

Maarten J Postma  1   2 , Chih-Yuan Cheng  3 , Nasuh C Buyukkaramikli  3 , Luis Hernandez Pastor  3 , Ine Vandersmissen  4 , Thierry Van Effelterre  3 , Peter Openshaw  5 , Steven Simoens  6
Affiliations

Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium

Maarten J Postma et al. Vaccines (Basel). .

Abstract

Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection (ARI) in older adults. This study used a static, cohort-based decision-tree model to estimate the public health and economic impact of vaccination against RSV in Belgians aged ≥60 years compared with no vaccination for different vaccine duration of protection profiles from a healthcare payer perspective. Three vaccine protection durations were compared (1, 3, and 5 years), and several sensitivity and scenario analyses were performed. Results showed that an RSV vaccine with a 3-year duration of protection would prevent 154,728 symptomatic RSV-ARI cases, 3688 hospitalizations, and 502 deaths over three years compared to no vaccination in older adults and would save EUR 35,982,857 in direct medical costs in Belgium. The number needed to vaccinate to prevent one RSV-ARI case was 11 for the 3-year duration profile, while it was 28 and 8 for the 1- and 5-year vaccine duration profiles, respectively. The model was generally robust in sensitivity analyses varying key input values. This study suggested that vaccination could substantially decrease the public health and economic burden of RSV in adults ≥60 years in Belgium, with benefits increasing with a longer duration of vaccine protection.

Keywords: health economic evaluation; older adults; respiratory syncytial virus; vaccine.

PubMed Disclaimer

Conflict of interest statement

M.J.P. holds stocks in Health-Ecore (Zeist, Netherlands) and PAG BV (Groningen, Netherlands). C.-Y.C., N.C.B., L.H.P., I.V. and T.V.E. are employees of Janssen Pharmaceuticals and may hold shares of Johnson & Johnson. T.V.E. also declares holding shares of GSK. P.O. has been a member of scientific advisory panels for GSK, Moderna, Janssen, Seqirus and Pfizer. S.S. has been involved in research on the value of vaccines funded by GSK, MSD, and Pfizer.

Figures

Figure 1
Figure 1
Model structure featuring no vaccination versus vaccination.
Figure 2
Figure 2
Tornado diagrams for (A) incremental number of RSV-related hospitalizations and (B) incremental total treatment costs (2022 euros).
See this image and copyright information in PMC

References

    1. Bergeron H.C., Tripp R.A. Immunopathology of RSV: An Updated Review. Viruses. 2021;13:2478. doi: 10.3390/v13122478. - DOI - PMC - PubMed
    1. Belongia E.A., King J.P., Kieke B.A., Pluta J., Al-Hilli A., Meece J.K., Shinde V. Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old. Open Forum Infect. Dis. 2018;5:ofy316. doi: 10.1093/ofid/ofy316. - DOI - PMC - PubMed
    1. Prasad N., Walker T.A., Waite B., Wood T., Trenholme A.A., Baker M.G., McArthur C., Wong C.A., Grant C.C., Huang Q.S., et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Adults with Chronic Medical Conditions. Clin. Infect. Dis. 2021;73:e158–e163. doi: 10.1093/cid/ciaa730. - DOI - PubMed
    1. Wyffels V., Kariburyo F., Gavart S., Fleischhackl R., Yuce H. A Real-World Analysis of Patient Characteristics and Predictors of Hospitalization Among US Medicare Beneficiaries with Respiratory Syncytial Virus Infection. Adv. Ther. 2020;37:1203–1217. doi: 10.1007/s12325-020-01230-3. - DOI - PMC - PubMed
    1. Widmer K., Griffin M.R., Zhu Y., Williams J.V., Talbot H.K. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir. Viruses. 2014;8:347–352. doi: 10.1111/irv.12234. - DOI - PMC - PubMed

LinkOut - more resources